


Figure S1 Study design



*In each dose cohort, eight subjects were randomized 6:2 to receive a single administration of evobrutinib or placebo. The first two subjects were dosed initially with evobrutinib or placebo (1:1) on day 1, with the remainder (5:1) dosed after 24 h if safety was deemed satisfactory.

†In each dose cohort, 12 subjects were randomized 9:3 to receive a single administration of evobrutinib or placebo.

FU, follow-up; SD, single dose; SMC, Safety Monitoring Committee